Examples include receptor tyrosine complexes, ion channels, transporters, and G protein-coupled receptors (GPCRs). For the latter, there is abundant evidence indicating that GPCRs assemble into complexes, through both homo-and heterodimerization. However, the tools for studying and disrupting these complexes, GPCR or otherwise, are limited. Here, we have developed stabilized interference peptides for this purpose. We have previously reported that tetrahydrocannabinol-mediated cognitive impairment arises from homo-or heterooligomerization between the GPCRs cannabinoid receptor type 1 (CB 1 R) and 5-hydroxytryptamine 2A (5-HT 2A R) receptors. Here, to disrupt this interaction through targeting CB 1 -5-HT 2A receptor heteromers in HEK293 cells and using an array of biochemical techniques, including calcium and cAMP measurements, bimolecular fluorescence complementation assays, and CD-based helicity assessments, we developed a NanoLuc binary technology (NanoBiT)-based reporter assay to screen a small library of aryl-carbon-stapled transmembrane-mimicking peptides produced by solid-phase peptide synthesis. We found that these stapling peptides have increased ␣-helicity and improved proteolytic resistance without any loss of disrupting activity in vitro, suggesting that this approach may also have utility in vivo. In summary, our results provide proof of concept for using NanoBiT to study membrane protein complexes and for stabilizing disrupting peptides to target such membrane complexes through hydrocarbon-mediated stapling. We pro-pose that these peptides could be developed to target previously undruggable GPCR heteromers.
The discovery that G protein-coupled receptors (GPCRs) 3 could oligomerize, termed homo-or heterodimerization, sparked an intense debate that has moved on from whether they can oligomerize to why, how, and how frequently they oligomerize and how we might target oligomers for therapeutic purposes. Several X-ray-resolved GPCR crystal structures have revealed common dimeric interfaces stabilizing oligomeric arrangements within the rhodopsin-like family receptors. Dimers having an interface involving the transmembrane (TM) domains TM1, TM2, and H8 appear to be a commonly conserved organization, including the structures of the rhodopsin, opsin, metarhodopsin II,and -opioid, and ␤1 adrenergic receptors (1) (2) (3) (4) (5) (6) . An additional interface involving the TM4 and TM5 domains was also shown in the squid rhodopsin and the ␤ 1 -adrenergic receptors (2, 7) . Furthermore, the crystal structures of the CXCR4 and -opioid receptors revealed a substantial buried surface area of 850 and 1,492 Å 2 , respectively, comprised of the TM5 and TM6 domains (3, 8) . Selective disruption of dimers using synthetic peptides harboring the same amino acid sequence as the interacting TM domains has helped to validate and understand the functional consequences of receptor oligomerization, including the ␤ 2 -adrenergic, CXCR4, oxytocin, and apelin receptor homooligomers (9 -12) . Synthetic peptides have also provided unique tools to map the interfaces and understand the biological relevance of class A GPCR het-eromerization (13, 14) . An additional advantage of TM peptides is that, unlike in knockout studies or deletions, the peptides preserve the functional single protomers and allow one to discriminate between those effects driven by the interacting receptors and those derived from the individual protomers. An example of the former is the in vivo disruption of the cross-class angiotensin receptor subtype 1a (AT1aR) and secretin receptor heteromers with a TM1 AT1aR mimetic peptide, reducing hyperosmolality-induced drinking behavior (13) .
In cases where heteromer disruption might serve a therapeutic purpose, it would be advantageous to translate TM peptides not only as tools, but into druglike entities. Peptides in general are considered poor druglike molecules, although this view is changing. Efficacy is often compromised in vivo due to a loss of secondary structure; cellular uptake is poor, and finally peptides are highly susceptible to proteolysis. Stapling of the peptide backbone can help to overcome these limitations; the bioactive conformation of the peptide is maintained, and careful positioning and choice of staple can result in a high-affinity binder with improved cellular uptake and stability. Stapled peptides therefore represent an attractive approach to developing more druglike peptides. For a recent review on stapled peptides, see Ali et al. (15) . We have shown previously that the undesired effect of cognitive impairment in the presence of trans-⌬9-tetrahydrocannabinol (THC) is driven by homo-/heterooligomerization between CB 1 and 5-HT 2A receptors (16) . To disrupt this interaction, we developed a NanoLuc binary technology (Nano-BiT)-based assay for the screening of a small library of arylhydrocarbon-stapled CB 1 R TM5-mimicking peptides to target CB 1 -5-HT 2A receptor heteromers. NanoBiT is a luciferasebased complementation assay designed to interrogate proteinprotein interactions in live cells (17) . Using this approach, we found that stapling peptides led to increased ␣-helicity and improved proteolytic resistance without any loss of function, suggesting that this approach may improve these molecules chances in vivo.
Results

Establishing the NanoBiT system for heteromer-screening purposes
The CB 1 and 5-HT 2A receptor heteromer has been recently characterized both in vivo and in heterologous expression systems using a broad range of biochemical approaches (16) . In the case of these heteromers, the cognitive impairment induced by THC is abrogated after treatment with CB 1 R TM5 peptides while maintaining its antinociceptive properties (16) . Therefore, for therapeutic purposes, there needs to be prevention of heteromer formation but preservation of the individual protomer's function. Thus, we first sought to develop a Nano-BiT-based assay for the screening of a small library of hydrocarbon-stapled CB 1 R TM5-mimicking peptides. To assess whether NanoBiT BiLC may be a suitable system to study GPCR oligomerization, we generated CB 1 R and 5-HT 2A R constructs with the small and large BiT pairs (SmBiT and LgBiT, respectively) attached to the C terminus end of both receptors. A total of four fusion proteins were generated, with Sm/LgBiT fused after the Gly/Ser-rich flexible linker and under the con-trol of the herpes simplex virus thymidine kinase gene promoter (HSV-TK) ( Fig. S1A ). Next, we performed conformational screenings to assess the optimal configuration for all receptor pairs. Accordingly, when analyzing CB 1 R-5-HT 2A R heteromers, HEK293 cells were transiently transfected with all possible combinations of 5-HT 2A R Lg/SmBiT and CB 1 R Lg/SmBiT at two different DNA ratios ( Fig. S1B) . Surprisingly, none of the analyzed configurations yielded a positive interaction. Similarly, when addressing the formation of CB 1 R and 5-HT 2A R homodimers, none of the examined orientations or DNA ratios exhibited significant differences compared with the individual receptors when expressed by themselves ( Fig. S1 , C and D). Importantly, to rule out whether these negative results might reflect the unsuitability of the NanoBiT system for the analysis of GPCR oligomerization rather than any kind of experimental hindrance, we analyzed the known interaction between the protein kinase A catalytic (PRKACA) and type 2A regulatory (PRKAR2A) subunits. This protein pair positive control has been previously optimized, with LgBiT-PRKAR2A and SmBiT-PRKACA the optimal configuration (17) . In agreement, cotransfection of both proteins resulted in a significant increase in the luminescence recorded over the different receptor ratios. Furthermore, co-transfection of LgBiT-PRKAR2A with a noninteracting fusion protein (HaloTag-SmBiT) did not yield any increase in luminescence ( Fig. S1E ), supporting the specificity of the detected interaction and the suitability of this system under our assay conditions. However, our results do not reveal if the complementary fusions restrict 5-HT 2A R or CB 1 R functionality or if there is indeed a lack of complementation. Importantly, it should be noted that to minimize potential nonspecific interactions, all generated constructs were under the control of the HSV-TK promoter.
Thus, to address the lack of a BiLC signal, we performed secondary messenger signaling experiments and recloned all four receptor configurations under the control of the high-level expression cytomegalovirus (CMV) promoter. Interestingly, all 5-HT 2A R constructs in an HSV-TK context failed to elicit intracellular calcium release (canonical signaling pathway downstream to the G q/11 -coupled 5-HT 2A R) after agonist stimulation (18) . However, both 5-HT 2A R LgBiT and 5-HT 2A R SmBiT displayed similar efficacies and potencies compared with the WT receptor when expressed under the control of the CMV promoter ( Fig. S2A ). Similarly, we assessed CB 1 R-driven adenylate cyclase inhibition with analogous results. Both CMV-regulated CB 1 R constructs inhibited the forskolin-induced cAMP release with equivalent potencies and efficacies to the WT CB 1 R receptor. However, under the HVS-TK promoter, CB 1 R LgBiT failed to signal through heterotrimeric G i/o proteins, and CB 1 R SmBiT exhibited a reduced adenylate cyclase inhibitory activity (ϳ20%) when compared with WT CB 1 R receptor ( Fig.  S2B ). These results indicate that the NanoBiT fusions do not adversely affect 5-HT 2A or CB 1 receptor functionality, as the ligand potencies and maximal efficacies are within the WT receptor ranges. Thus, the absence of luciferase complementation between HSV-TK-regulated constructs most likely reflects low levels of receptor expression due to the weaker promoter rather than steric hindrance of the interacting pairs (19) .
NanoBiT can be used to estimate receptor affinities
Accordingly, as in the previous studies illustrated in Fig. 1A , we repeated the conformational screenings with the new set of constructs under the CMV promoter. When analyzing 5-HT 2A R-CB 1 R heteromerization, we detected a significant increase in the luminescence for all receptor combinations, with 5-HT 2A R LgBiT:CB 1 R SmBiT being the optimal pair in terms of assay window (Fig. 1B) . To validate the specificity of the interaction, increasing amounts of untagged 5-HT 2A R and CB 1 R receptors were transfected in the presence of a fixed 5-HT 2A R LgBiT:CB 1 R SmBiT ratio. Accordingly, we observed a decreased luminescence with increasing levels of both untagged proteins (Fig. 1, E and F) , indicating that the detected interaction was not driven by the finite affinity between the NanoLuc subunits. In parallel, we assessed CB 1 R and 5-HT 2A R homomerization with similar results. Co-transfection of both CB 1 R-interacting pairs resulted in a significant increase in luminescence that could be reverted by increasing untagged CB 1 R concentrations ( Fig. 1, C and G) . Similarly, the specific interaction between 5-HT 2A R LgBiT and 5-HT 2A R SmBiT was hindered when titrating increasing concentrations of untagged 5-HT 2A R (Fig. 1, D and H) . Importantly, when comparing the relative intensities of these interactions, we found that 5-HT 2A R homodimers displayed the highest luminescent signals, followed by 5-HT 2A R-CB 1 R heteromers and CB 1 R homodimers (RLU for 5-HT 2A R:5-HT 2A R Ͼ 5-HT 2A R:CB 1 R Ͼ CB 1 R:CB 1 R). In addition, higher nontagged 5-HT 2A R concentrations were necessary to displace 5-HT 2A R homodimers ( Fig.  1H ). However, our results cannot discriminate whether it reflects the relative affinities between the interacting receptors or a more proximal distance of the NanoBiT pairs in the C terminus of the receptors. Altogether, our data strongly support NanoBiT BiLC as a nondestructive and powerful tool to study GPCRs oligomerization, providing a specific and sensitive assay to detect these receptor complexes in live cells.
Comparison of NanoBiT with Venus bimolecular fluorescent complementation
To obtain a more comprehensive understanding of bimolecular complementation assays to study GPCR oligomerization, we sought to address whether NanoBiT could provide better results compared with bimolecular fluorescent complementation. To this end, we developed a Venus bimolecular fluorescent complementation (BiFC) assay to study CB 1 R and 5-HT 2A R homo-/heteromerization. Specifically, fragments derived from the truncated Venus fluorescent protein at either position Asp-155 (VC155; amino acid residues 155-238) or Asp-173 (VN173; amino acid residues 1-173) were fused after the Gly/Ser-rich flexible linker to the C terminus of both CB 1 and 5-HT 2A receptors ( Fig. 2A ). This strategy has been extensively applied to the study of protein-protein interactions (PPIs) and takes advantage of Venus, a variant of the enhanced yellow fluorescent protein (YFP) with improved sensitivity to chromophore maturation under physiological temperatures (21) . Several groups have used this approach to study GPCR oligomerization, including heteromers between the adenosine A 2A and the dopamine D 2 receptors, dopamine D 2 oligomers, or neuropeptide Y Y 1 /Y 5 receptor heterodimers (19 -21) .
Attachment of both Venus hemiprotein fragments to the 5-HT 2A R C-terminal tail (5-HT 2A R-VN173 and 5-HT 2AR -VC155 constructs) did not impact receptor function, with equivalent [Ca 2ϩ ] i release dose-response curves compared with the WT receptor ( Fig. S3A) . Similarly, the VC155 fragments fused to CB 1 R (CB 1 R-VC155) did not affect CB 1 R-mediated cAMP release inhibition. However, although its maximal efficacy remained unaltered, VN1733 fusion to CB 1 R (CB 1 R-VN173) resulted in ϳ10-fold reduction in WIN 55212-2 (WIN) potency ( Fig. S3B ). Next, we proceeded to compare both protein complementation assays. For CB 1 R and 5-HT 2A R homomers, BiFC experiments were performed under the same conditions that yielded the optimal assay windows in the NanoBiT BiLC experiments (Fig. 2) . When assessing 5-HT 2A R-CB 1 R heteromers, both possible receptor configurations (5-HT 2A R-VN173:CB 1 R-VC155 and 5-HT 2A R-VC155:CB 1 R-VN173) were taken into account. Surprisingly, 24 and 48 h after reverse transfection, none of the analyzed BiFC combinations yielded significant fluorescent levels (data not shown), suggesting timedependent protein maturation and/or folding. Therefore, the following BiFC experiments were performed 48 h post-transfection (see "Experimental procedures"), although BiLC assays remained under the same setup (24 h post-transfection). Compared with Venus BiFC, NanoBiT complementation provided higher assay windows over all of the oligomeric configurations ( Fig. 2) . Specifically, we observed a 20-fold increase for CB 1 R homodimers, 130-fold increase for 5-HT 2A R homodimers, and 9 -18-fold increase for 5-HT 2A R-CB 1 R heteromers. Interestingly, the relative fluorescent/luminescent intensities for the different receptor pairs followed the same trend across both methods (RFU/RLU for 5-HT 2A R:5-HT 2A R Ͼ 5-HT 2A R: CB 1 R Ͼ CB 1 R:CB 1 R), suggesting that this could reflect the affinity between these oligomeric arrangements.
N-terminal GPCR fusions are also functional for NanoBiT complementation
Next, we sought to test whether N-terminal tagging might yield better assay windows ( Fig. 3A ). SmBiT and LgBiT fusion to the 5-HT 2A R extracellular end did not impact function, as treatment with the agonist (Ϯ)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI) induced maximal calcium release, although a small reduction in DOI potency was observed in the LgBiT-5-HT 2A R construct (Fig. S4A ). The homologous CB 1 R constructs remained unaltered, with virtually the exact potencies and maximal responses as the WT receptor ( Fig. S4B ). Next, we compared N-or C-terminal NanoBiT-tagged receptors, accounting for their ability to reveal CB 1 R and 5-HT 2A R homo-/heteromers. When measuring the interaction between receptors from the same type, NanoBiT attachment to the C-terminal domain provided the optimal orientation for CB 1 R homomers ( Fig. 3B ). In the case of 5-HT 2A R homomers, N-terminally tagging resulted in a discrete but significant improvement in the assay window at high DNA concentrations ( Fig.  3B ). Interestingly, the biggest difference was observed when assessing the optimal 5-HT 2A R-CB 1 R heteromeric conformation, with the N-terminal fusions providing the best results ( Fig. Stapled TM peptides modulate GPCR oligomers 3C) . Importantly, a ϳ200-fold increase was achieved at low DNA-transfected concentrations, therefore reducing the probability of stochastic nonspecific interactions and thus more closely mimicking physiological expression levels. The LgBiT-CB 1 R and SmBiT-5-HT 2A R combination was therefore used in all further experiments.
Design and synthesis of stapled peptides
In previous studies, we demonstrated that 5-HT 2A R-CB 1 R heteromers could be selectively disrupted using synthetic peptides mimicking the CB 1 R TM5 and TM6 domains (16) , fused to the HIV-TAT (GRKKRRQRRR) cell-penetrating amino acid sequence (CPS) (23). In the same study, we also showed that the peptide mimicking CB 1 R TM7 did not disrupt the heteromer. As part of our preliminary work, we had previously identified a truncated CB 1 R TM5 amino acid sequence fused to TAT (VYAYMYILWGRKKRRQRRR) capable of disrupting the 5-HT 2A R-CB 1 R heteromer. 4 We therefore chose to design sta-pled peptides based on the amino acid sequences of the truncated CB 1 R TM5 to aid with the synthesis and purification of the peptides as well as solubility. In addition, amino acid sequences of 20 -25 amino acid residues or less are generally recommended for stapling (24) .
Accordingly, using these structures as a starting point, we hypothesized that shortening their length, in combination with hydrocarbon peptide stapling, could result in peptides with more druglike properties ( Fig. 4A ). This strategy, through the incorporation of ␣-methyl-␣-alkenyl amino acids, combines the methylation of the ␣-carbon atom together with the introduction of a covalent side chain-to-side chain cross-link, resulting in peptides with increased ␣-helicity and improved proteolytic resistance (25, 26) . We next evaluated where to add the hydrocarbon staples. One major consideration is charge. An overall positive net charge is favorable after staple installation to aid with cellular uptake. The location of the positive amino acids is also influential and if possible should be located at the C terminus. Molecular modeling identified potential sites within these TM5 peptide amino acid sequences to introduce 
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the hydrocarbon staple ( Table 1 ). The positions (facing the membrane of CB 1 R) to build the stapled peptides (at i and i ϩ 3 ⁄ 4) are shown in red. The TAT amino acid sequence is shown in orange.
Peptides are often thought of as poor drug molecules, as 1) in vivo their efficacy is compromised due to a loss of secondary structure, 2) they often have poor cellular uptake, and 3) they are highly susceptible to proteolysis. Stapling of the peptide backbone is an attractive strategy to overcome these limitations; the bioactive conformation of the peptide is maintained, and careful positioning and choice of staple can result in a highaffinity binder with improved cellular uptake and stability. Next is the choice of staple to use. We chose to incorporate the allhydrocarbon staple for ␣-helical peptide stabilization. This was first reported in 2000 by Schafmeister et al. (27) and has since found use in a variety of applications, including cancer, infectious diseases, and neuroscience (28) . In addition, this staple has been shown to protect the peptide against proteolysis as the vulnerable peptide bonds are sequestered in the interior of the helix. The building block for single-turn hydrocarbon stapling is the unnatural amino acid S-pentenylalanine (Fmoc-S 5 -OH). Although available commercially, we chose to synthesize the Fmoc-protected version in-house, adapting methods reported by Jamieson and Ryzhov (Scheme 1) (29, 30) . Briefly, N-alkylation of proline with 2-fluorobenzyl bromide gave 1 in almost quantitative yields. This was followed by the condensation of 1 with 2-aminobenzophenone to give the chiral auxiliary (S)-N-
Complexation with nickel nitrate and L-alanine gave (S)-Ni-Ala-2FBPB 3 in almost quantitative yields. This was followed by asymmetric alkylation to yield complex 4 in a good yield, which was subsequently decomposed under acidic conditions to give S-pentenylalanine 5. Finally, this was Fmoc-protected by reaction with Fmoc chloride under basic conditions to afford Fmoc-S-pentenylalanine 6. Following synthesis of the unnatural amino acid, we turned our attention to the synthesis of the CB 1 R TM5 peptides.
Five peptides (7) (8) (9) (10) (11) were designed for our study, including one negative control (11) (Fig. 4A ). Methionine amino acid residues were replaced with norleucine amino acid residues to avoid any complications or unwanted side reactions during ring closing metathesis reactions. Peptides were synthesized using Fmoc-based solid-phase peptide synthesis using procedures reported previously (9) . Scheme 2 outlines an example synthe- Stapled TM peptides modulate GPCR oligomers sis. During assembly, the Fmoc-S 5 -OH is incorporated into positions separated by 2 or 3 amino acid residues, as shown in Fig. 4A . Coupling times were increased from 45 min to 60 min for the Fmoc-S 5 -OH and for the residue following the olefinic unnatural amino acid. The assembled peptides (7-10) were then subjected to the ring-closing metathesis (RCM) reaction while still on the solid support. This was monitored using reversed-phase HPLC (RP-HPLC); note that peptide 7 did not undergo the RCM reaction. Following a final Fmoc deprotection step, the stapled peptides were cleaved from the solid support under acidic conditions and subsequently purified using preparative RP-HPLC and freeze-dried from water as described previously (30) . The negative control 11 was treated in an identical fashion with the exception that the RCM step was omitted. Purified peptides were analyzed using analytical RP-HPLC to assess purity and MALDI-TOF MS to determine accurate mass. All peptides were soluble in water/aqueous buffer.
The administration of peptides to disrupt GPCR interactions is relatively new, with no available information regarding their pharmacokinetics and/or pharmacodynamics. Often with peptides, the in vivo efficacy is compromised due to a loss of secondary structure; to assess the helicity of the peptides and whether incorporation of the staple had increased the helical nature of the peptides, we employed CD spectroscopy ( Fig. 4B ). CB1 TM5-TAT, TM6-TAT, and TM7-TAT all displayed relatively low helicity in solution (less than ϳ20%). Incorporation of the staples increased the helical nature of the stapled peptides 8 -10 in all cases when compared with the TM5-TAT peptide. Peptide 8 demonstrated the highest helicity of 58.3%. Interestingly, the negative control 11, where the olefinic amino acids are present but not stapled, displayed an almost identical helicity (46.0%) when compared with the stapled version 9. When TAT is added to the amino acid sequence 10, the helicity drops slightly to 36.8%. A second challenge facing protein/peptide therapies is proteolytic degradation. Consequently, we subjected our peptide library to in vitro trypsin, chymotrypsin, and serum proteolytic stability. When monitoring trypsin (0.55 g/ml) degradation kinetics (Fig. 4E ), a rapid proteolysis was observed for the TM7-TAT, TM6-TAT, and TM5-TAT control peptides (55 M each), with half-lives ranging from 20 to 40 min. The short-stapled CB 1 R TM5 amino acid sequence harboring the TAT amino acid sequence 10 displayed a longer half-life, with a 2-3-fold enhancement in trypsin resistance. Furthermore, removal of the TAT amino acid sequence in the stapled peptides (8 and 9) yielded the longest half-lives (ϳ5 h), as neither lysine nor arginine amino acid residues were available for the trypsin to cleave. This increase in half-life was also observed for the negative controls where the TAT amino acid sequence was removed. Chymotrypsin proteolytic kinetics showed similar results (Fig. 4F) ; the full-length TM7-TAT, TM6-TAT, and TM5-TAT peptides were more susceptible to cleavage (half-lives ranging from 20 to 30 min). Again, a ϳ2-fold resistance improvement was detected for stapled peptide 10 bearing the TAT amino acid sequence. Likewise, 8 and 9 were the peptides with longer half-lives (5-6 h) (Fig. 4F) . In mouse serum, a more physiologically relevant context, the TM7-TAT, TM6-TAT, and TM5-TAT peptides were rapidly degraded, with a 1-h incubation sufficient to break down 50% of them ( Fig. 4G ). Hydrocarbon stapling translated to an even higher serum stability compared with trypsin and chymotrypsin, with peptides 8 and 9 displaying half-lives of more than 10 h. These results positively correlate with the respective helicity of each peptide, as the reinforcement of ␣-helical structure limits the peptides to adopt the extended conformation required by proteases to hydrolyze the amide bonds (25) . Accordingly, we observed a strong positive correlation between helicity and proteolytic resistance (r ϭ 0.84, 0.78, and 0.87 for trypsin, chymotrypsin, and mouse serum, respectively; Fig. 4 , C and D). Finally, we investigated the effects of the peptides on cell proliferation and toxicity using a label-free assay. Specifically, we analyzed cell viability based on changes in electrical impedance over time. No statistically significant reduction in viability of the cells was observed over a 24-or 48-h period (Fig. S5 ).
Stapled peptides are effective at disrupting heteromers
Next, we sought to test whether stapling changed the ability of the peptides to disrupt GPCR heteromers (schematic in Fig.  5A ). Preincubation of HEK293 cells transiently co-expressing LgBiT-CB 1 R and SmBiT-5-HT 2A R with the TM5-TAT and TM6-TAT, but not the TM7-TAT (negative control), peptides resulted in a decrease in the luminescence readout ( Fig. 5B) , corroborating the previously reported results demonstrating the involvement of TM5 and TM6, but not TM7, in the heteromeric interface (16) . In addition, these results demonstrate the suitability of our NanoBiT-based peptide screening assay and the specificity of the detected interaction.
Next, we tested whether the stapled versions were as efficient at blocking heteromerization (Fig. 5B) . When analyzing the TM5-TAT-derived peptides, compound 10 exerted a signifi- Potential sites within the CB 1 R TM5 peptide amino acid sequence to introduce the hydrocarbon staple were identified based on a previously published molecular model (see "Experimental procedures")
The positions (facing the lipids) to build the stapled peptides (at i and i ϩ 3 4 ) are shown in red. The TAT amino acid sequence is shown in orange.
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cant decrease in NanoBiT complementation. Interestingly, however, neither the version lacking the TAT amino acid sequence, compound 9, nor the nonstaple, compound 11, peptides induced any change. It was not simply length of the peptide, as the longer stapled compound 8 also was not as efficient as compound 10 at disrupting the complex. Stapling in itself did not seem to convey an advantage as, comparing compounds 9 and 11, we observed equal effects.
We next sought to understand the disruption efficacy and the timing of compound 10's effects on the heteromer. Treatment with increasing concentrations of compound 10 induced a dose-dependent luminescence decrease, with a potency in the low micromolar range (pIC 50 ϭ 5.47 Ϯ 0.01) ( Fig. 5C ). Surprisingly, the ability of compound 10 to disrupt 5-HT 2A R-CB 1 R heteromers was on the order of minutes, reaching its maximal inhibitory response approximately 5 min after administration (Fig. 5D ).
Altogether, by developing a sensitive and specific bimolecular luminescent complementation assay, we were able to screen a small library of peptides targeting 5-HT 2A R-CB 1 R heteromers. In addition, covalent side chain-to-chain cross-linking through hydrocarbon peptide stapling led us to the identification of a small TM peptide mimetic, 10, with improved stability, helicity, and efficacy.
Discussion
Here we have successfully provided a proof of concept for two new tools to study GPCR oligomerization. First, we successfully applied the recently developed NanoBiT to study GPCR oligomerization. Using this system, we validated the previously demonstrated association of CB 1 R and 5-HT 2A receptors as homodimers and their ability to form heteromers (16, 31, 32) . Second, we have demonstrated that interference peptides can be dramatically stabilized and shortened using arylcarbon stapling. These two advances will prove useful in studying GPCR oligomerization both in vitro and particularly in vivo.
When adapting the NanoBiT to study oligomerization, we predicted that the small size of the complementary fragments (18 and 1.3 kDa for LgBiT and SmBiT, respectively), would minimize steric conflicts (17) . In fact, agonist potencies and maximal efficacies were equivalent to their matched WT receptors under the same promoters. Apart from GLuc (19 kDa), NLuc (19 kDa) is significantly smaller compared with other fluorescent/luminescent proteins used in resonance energy transfer or protein complementation assays (ranging from 26 kDa for YFP up to 61 kDa for FLuc). In addition, no post-translational modifications have been reported in mammalian cells, resulting in lower energetic costs in terms of translation, sorting and proper polypeptide folding. Accordingly, our initial studies were performed under the control of the low-copy number herpes simplex virus thymidine kinase gene promoter (HSV-TK) (19) . However, under this configuration, we were not able to quantitatively assess agonist-induced downstream signaling pathways. Importantly, most DNA constructs for FRET/BRET and BiFC assays use transient expression systems, such as pcDNA3.1 vectors, with the cDNA expressed under the control human CMV immediate-early enhancer and promoter (33, 34) . Using this strategy, we developed a microtiter-based homogeneous assay that allowed the identification of GPCRs oligomers in just 24 h, reducing the chance of overexpressionrelated nonspecific interactions. When comparing our Nano-BiT-based dimerization assay with Venus YFP BiFC, an approach used to visualize more than 200 PPIs, including many GPCR homo-/heteromers (22) , NanoBiT BiLC proved far more sensitive at detecting CB 1 R and 5-HT 2A R homodimers and 5-HT 2A R-CB 1 R heteromers. Presumably, the small size of the fused fragments, NanoLuc high quantum yield, and the lack of BiFC maturation step act synergistically to allow us to detect PPIs 24 h after transfection under physiological conditions. More recently, TANGO and SPARK have been developed to study PPIs (35, 36) . Both are good approaches for larger screens or, in the case of SPARK, enrichment of cell populations by FACS. The NanoBiT system adapted here is good for studies directly interrogating the interactions themselves, say for mapping the interactions themselves or testing known small molecules as we have shown in this study. Previously, a split
Scheme 1. Synthesis of the Fmoc-protected unnatural amino acid S-pentenylalanine (Fmoc-S 5 -OH).
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NanoLuc system was published to study G-protein signaling, but it does not have the advantage of having a short peptide portion on one of the partners as is used in the NanoBiT system (37) .
Interference peptides have been used in multiple studies to validate or disrupt GPCR heteromers (9, 13, 16, 38, 39) . However, these peptides often suffer from poor pharmacokinetics and have a poor chance of being used or developed into druglike entities. To improve on the potential of such entities to be adapted as potential therapeutics, we have stabilized a disrupting peptide using hydrocarbon stapling. This approach has been used on a variety of peptide therapeutics. However, to our knowledge, stapled peptides have not been applied to G protein-coupled receptor oligomers. We demonstrate here that stapling of disrupting peptides can significantly shorten the required length of the peptide and dramatically improve the stability of the peptides. These data support further development of such an approach to target GPCR oligomers in vivo.
An additional challenge presented in targeting such complexes is that the same membrane polypeptide can often interact with multiple partners in different complexes (e.g. dopamine 2 receptor can interact with A2a receptor as well as dopamine 1 receptor, or different N-methyl-D-aspartate subunits or ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid subunits can make up multiple complexes). To date, we have not seen that disrupting peptides are specific for a given complex. Our evidence here that additional modifications can be made to these peptides provides an opportunity for adding additional chemical modifications that might provide more complex specificity in the future.
Experimental procedures
Reagents
Unless stated otherwise, reagents and solvents were purchased as high-grade commercial products from Sigma-Aldrich. (R)-(ϩ)-WIN 55212 and DOI were purchased from Tocris Bioscience.
Expression vectors and cloning
Plasmids encoding the 3xHA-tagged human 5-HT 2A and CB 1 receptors were obtained from the cDNA Resource Center (catalog numbers HTR02ATN01 and CNR010TN01, respectively). Plasmids encoding the pGloSensor TM -22F cAMP biosensor and the complementary NanoBiT pairs (pBiT1. All constructs generated in this study were generated following the Gibson assembly method according to the manufacturer's instructions (Gibson Assembly Master Mix, New England Biolabs). Detailed information is provided in Table S1 . The cor- 
Cell culture and transfection
Human embryonic kidney 293 (HEK293) cells (ATCC CRL-1573 TM ) were grown in Dulbecco's modified Eagle's medium supplemented with 2 mM L-glutamine, 4.5 g/liter D-glucose, 100 g/ml sodium pyruvate, 100 units/ml penicillin, 100 g/ml streptomycin, and 10% (v/v) heat-inactivated fetal bovine serum (PAN-Biotech, Aidenbach, Germany) at 37°C in a 5% CO 2 humidified atmosphere. Cells were directly transfected in a 96-well plate format following the reverse Lipofectamine TM 3000 (Thermo Fisher Scientific) transfection method. Briefly, for each well, 100 -200 ng of DNA and 0.2-0.4 l of P3000 TM reagent (1:2 (w/v) DNA: P3000/Lipofectamine TM 3000 ratio) were combined in 25 l of Opti-MEM medium. The total amount of DNA/well was kept constant with empty vector (pcDNA3.1). In a separate tube, 0.2-0.4 l of Lipofectamine TM was added to 25 l of Opti-MEM medium. Both reaction mixes were vortexed (2-5 s) and incubated at RT for 5 min. After this time, the diluted DNA was added dropwise to the Lipofectamine TMcontaining tube, gently mixed by pipetting up and down, and incubated for 15 min at RT. In parallel, cells were trypsinized according to standard mammalian tissue culture protocols and resuspended in complete cell culture medium to 5 ϫ 10 5 viable cells/ml. 100 l of the cell suspension was distributed into each well, and 50 l of the transfection mix was added on top of the cells. The plates were then incubated at 37°C in a 5% CO 2 humidified atmosphere for 24 -48 h before performing the experiments.
Ca 2؉ and cAMP measurement
For [Ca 2ϩ ] i release quantification, 50,000 cells/well were reverse-transfected (see above) with 50 ng/well of pGP-CMV-GCaMP6s calcium sensor vector and 100 ng/well of receptor in poly-D-lysinecoated black clear bottom 96-well plates. 24 h post-transfection, the cell culture medium was removed, and the cells were starved in FBS-free DMEM for 4 h at 37°C in a 5% CO 2 humidified atmosphere. Prior to [Ca 2ϩ ] i release measurements, the cell culture medium was replaced by 175 l of Ca 2ϩ assay buffer (145 mM NaCl, 2.5 mM KCl, 10 mM glucose, 10 mM HEPES, 2 mM CaCl 2 , 1 mM MgCl 2 , pH 7.4), and the plates were pre-equilibrated for 1 h in the dark at 37°C in a 5% CO 2 humidified atmosphere. Immediately following agonist addition (25 l, 8ϫ final concentration), fluorescence emission intensity was recorded at 515 nm upon excitation at 488 nm in a CLARIOstar multimode plate reader (BMG Labtech, Ortenberg, Germany) for 300 s every 5 s and 40 flashes/well at 37°C. To account for differences in expression/cell density, an aver-age of five prereadings were used to normalize each well's response.
cAMP measurements were performed as described previously (40). Briefly, 24 h post-transfection, cells were incubated in FBS-free DMEM for 4 h at 37°C in a 5% CO 2 humidified atmosphere. Prior to cAMP measurements, the cell culture medium was replaced, and plates were pre-equilibrated for 1 h with cAMP assay buffer (Hanks' balanced salt solution with 24 mM HEPES, 3.3 mM NaHCO 3 , 1.3 mM CaCl 2 , 1 mM MgSO 4 , 0.1% (w/v) BSA, pH 7.4) supplemented with 0.45 mg/ml firefly D-luciferin free acid. Immediately after agonist addition, luminescence was recorded using a CLARIOstar multimode plate reader (BMG Labtech) with no lens (1-s integration time/well for 1 h every minute). To account for differences in expression/ cell density, an average of six prereadings were used to normalize each well's response.
NanoBiT BiLC and Venus BiFC assays
To assess GPCR protein-protein interactions with the NanoBiT technology, HEK293 cells (50,000 cells/well) were seeded in poly-D-lysinecoated white clear bottom 96-well plates and reverse-transfected (see above) with the plasmids encoding the complementary NanoBiT hemiprotein fragments. For orientation screenings, cells were transfected with two different concentrations (50 and 100 ng/well) of each receptor alone or in combination with the investigated partner (see figure legends) in the presence of empty vector (pcDNA3.1(ϩ)) to normalize the total amount of DNA/well. For studies in the presence of increasing nontagged receptor competitors, 100 ng of each receptor pair (CB 1 R LgBiT ϩ CB 1 R SmBiT, 5-HT 2A R LgBiT ϩ 5-HT 2A R SmBiT, and 5-HT 2A R LgBiT ϩ CB 1 R SmBiT) were co-transfected with increasing concentrations of the different nontagged constructs (from 0 to 300 ng/well), and the total amounts of DNA/well were normalized with empty vector (pcDNA3.1(ϩ)). For the screening of stapled peptides, 50 ng/well of both LgBiT CB 1 R and SmBiT 5-HT 2A R were reverse-transfected as detailed previously. 24 h post-transfection, the cell culture medium was removed, and the cells were starved in FBS-free DMEM for 4 h at 37°C in a 5% CO 2 humidified atmosphere. The cell culture medium was replaced by 100 l of NanoBiT assay buffer (same as for cAMP measurements), and the plates were pre-equilibrated for 1 h at RT in the dark. When peptide pretreatment was required, peptides were added over this pre-equilibration step, except when studying inhibition kinetics, when the peptides were administered immediately after the baseline luminescence recording. 25 l/well of a 5ϫ solution of the Nano-Glo live cell reagent containing the cell-permeable furimazine substrate dissolved in Nano-Glo LCS dilution buffer were added, and the luminescence was immediately monitored in CLARIOstar Multimode Plate Reader (BMG Labtech) with no lens (1-s integration time/ well for 1 h every minute).
For BiFC experiments, HEK293 cells growing at ϳ80% confluence in 6-well plates were transfected with Lipofectamine TM 3000 according to the manufacturer's instructions with 1.5 g/well of both Venus YFP complementary plasmids and the corresponding individual receptor constructs. The total amount of DNA/well was kept constant with empty vector Stapled TM peptides modulate GPCR oligomers (pcDNA3.1(ϩ)). 24 h post-transfection, the cells were trypsinized according to standard mammalian tissue culture protocols, and 5 ϫ 10 5 viable cells/ml were seeded in poly-Dlysine-coated black clear bottom 96-well plates and incubated at 37°C in a 5% CO 2 humidified atmosphere overnight. 48 h post-transfection, the cell culture medium was removed, and the cells were starved in FBS-free DMEM for 4 h at 37°C in a 5% CO 2 humidified atmosphere. Prior to fluorescence measurements, the cell culture medium was replaced with 100 l of NanoBiT assay, and the plates were pre-equilibrated for 1 h at RT in the dark. Venus YFP fluorescence was measured at 530 nm (540 -20 filter and 517.2-nm dichroic filter) upon excitation (40 flashes/well) at 489 nm (497-15 nm) in a CLARIOstar multimode plate reader (BMG Labtech) at 25°C.
Cell proliferation and toxicity assays
The iCELLigence real-time cell analyzer instrument (Roche Diagnostics GmbH and ACEA Biosciences) was used to analyze cell viability based on changes in electrical impedance over time (defined as cell index (CI)). Prior to the experiment, background CI levels of the 8-well E plate (ACEA Biosciences) were measured after the addition of 200 l/well of prewarmed complete cell culture medium (see below). Immediately after, 200 l of the cellular suspension (2.5 ϫ 10 5 viable HEK293 cells/ml) were distributed in each well, and cellular impedance was continuously monitored (time intervals are indicated in the respective figures) at 37°C in a 5% CO 2 humidified atmosphere. After 24 h, the E-plates were removed for peptide treatment (4 M) and immediately returned back to the real-time cell analyzer, and CI changes were monitored under the same conditions over the next 48 h. Normalized cell index refers to the ratio between the CI values and CI from the time point immediately prior to ligand addition.
Data analysis
Dose-response curves were fitted using a four-parameter logistic nonlinear regression mode. Peptide stability data were fitted using a nonlinear regression mode for dissociation kinetics. All statistical tests, curve fitting, and graphing were performed using GraphPad Prism 8 (GraphPad Software, La Jolla, CA). Information on the statistical test, significance, and experimental replicates is provided in the figure legends.
Positioning of the staple position
We previously published a model of the CB 1 -5-HT 2A heterodimer (16) . Using this model, we identified the amino acids of CB 1 R TM5 that would be facing outward from the CB1R receptor, and using an i ϩ 3, we located the amino acids on which to place the staples using the logic that the staples should be on the opposite side of the helix from the interface of the two receptors.
Synthesis of the unnatural amino acid
General procedure-All experiments were run under an atmosphere of nitrogen, using anhydrous solvents. All chemicals were purchased from Sigma-Aldrich. Analytical TLC was performed on Merck Kieselgel 60 F254 plates with visualization by UV light. Flash chromatography was performed on an Isolera TM Prime (Biotage AB, Uppsala, Sweden). Melting points are uncorrected and were obtained in open capillaries using an electrothermal melting point apparatus. NMR spectra were recorded on Bruker DPX ( 1 H, 400 MHz; 13 C, 100 MHz; 19 F, 376 MHz) spectrometers for CDC l 3 solutions. NMR chemical shifts (␦) are given in ppm relative to CDCl 3 at 7.26 ppm, and coupling constants (J) are reported in Hz. Spectral data are reported as follows: chemical shift, integration, multiplicity (s, singlet; d, doublet; t, triplet; m, multiplet). Optical rotations were measured on a JASCO P1010 polarimeter. High-resolution mass spectra were recorded at the National Mass Spectrometry Facility and Service at Swansea University Medical School (Swansea, UK).
Synthesis of (S)-1-(2-fluorobenzyl)pyrrolidine-2-carboxylic acid 1-L-Proline (8 g, 69.5 mmol) was added to a solution of freshly ground potassium hydroxide (11.7 g; 3 eq) previously dissolved in isopropyl alcohol (90 ml) at 40°C. As soon as the solution became transparent, 2-fluorobenzyl bromide (8.5 ml) was added dropwise, and the solution was stirred for 18 h at 40°C. Aqueous hydrochloric acid (37%) was added dropwise to the mixture until the solution reached pH 5-6, as determined using pH indicator strips. The suspension was then cooled in an ice bath for 15 min and filtered, and the precipitate was thoroughly washed with isopropyl alcohol. All filtrates were combined and concentrated in vacuo to give (S)-1- 13 
Synthesis and purification of the TM peptides
TM peptides were synthesized on a fully automated Syro I (Biotage) instrument using standard procedures for Fmoc-solid phase peptide synthesis on a 100-mg preloaded H-Arg(Pbf)-HMPB NovaPEG or H-Phe-HMPB NovaPEG resin (Merck Millipore, Darmstadt, Germany) with resin loading of 0.48 or 0.63 mmol/g, respectively, as a solid support. The preloaded arginine resin was swollen in DMF for 20 min and checked for potential clumping because clumped resin may impact the synthesis. After the swelling, coupling was achieved using 4 eq of the following: Fmoc-protected amino acid, HOBt (hydroxybenzotriazole) and HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium), and 8 eq of DIPEA (N,N-diisopropylethylamine) in NMP. Each coupling reaction was left for 45 min and performed twice to ensure complete coupling. Fmoc deprotection was achieved using 40% piperidine in DMF (3 ϫ 1.5 ml). After final incorporation of the last amino acid, the Fmoc group was removed, and the resin was washed thoroughly with DMF, DCM, and 1:1 DCM/MeOH to remove any residual DMF and dried in vacuo. Cleavage from the solid support was carried out using TFA/water/ethanedithiol/TIPS (v/v/v/v ϭ 94:2.5:2.5:1, 10 ml/0.1 g resin) in the case of TM5-7 for 3 h. For peptides 7-11, TFA/water/TIPS (v/v/v ϭ 95/2.5/2.5, 10 ml/0.1 g resin) was used. The resin was washed with TFA (10 ml), combined with the cleavage mixture, and concentrated in vacuo. The crude peptide was precipitated with a 10-fold excess of cooled (Ϫ20°C) diethyl ether, leaving a white precipitate.
Following crude peptide isolation, the peptides were dissolved in methanol (40 ml), filtered, and purified by preparative RP-HPLC (Agilent 1200 Infinity) using an Aeris PEPTIDE 5-m XB-C18 column, 150 ϫ 21.2 mm with a gradient of 95:5 water/MeOH with 0.05% TFA to 5:95 water/MeOH over 15 min returning to 95:5 water/MeOH over 5 min at a flow rate of 20 ml/min at the detection wavelength of 214 nm. Analytical RP-HPLC was then used to assess the purity of the products after the purification and was performed on an Agilent 1200 using an Aeris Peptide 5-m XB-C18 column, 150 ϫ 4.6 mm, with the same conditions as above. Following purification, the peptides were concentrated, resuspended in distilled water, and lyophilized. Mass analysis was performed to determine the identities of TM peptides by MALDI-TOF MS, using sinapinic acid as the ionization matrix.
Synthesis and purification of the stapled peptides
Peptides were synthesized on a Syro I fully automated peptide synthesizer using Rink amide LL 100 -200 mesh resin (0.36 mmol/g) at 36-mol scale as described above. Coupling frequency and incubation times were 2 ϫ 45 min for standard amino acid residues, 2 ϫ 60 min for the olefinic nonnatural amino acid 6, and 2 ϫ 60 min for the residue following a nonnatural amino acid. After the automated synthesis, the ringclosing metathesis was performed on the peptide while still on the solid support in a disposable fritted reaction vessel. The peptide resin was cyclized in the presence of Grubbs catalyst second-generation catalyst (10 mM) in anhydrous 1,2-dichloroethane (DCE) for 4 h at room temperature. Completeness of the RCM reaction was monitored by HPLC. The resin-bound peptide was washed with DCE and then with DCM, DCM/MeOH (1:1) and dried under vacuum. The Fmoc group was removed with 30% piperidine in DMF (2 ϫ 10 min), washed with DMF, DCM, DCM/MeOH (1:1), and dried under vacuum. The stapled peptides were cleaved from the solid support by treatment with TFA/H 2 O/TIPS (95:2.5:2.5) for 2-3 h at room temperature. The resin was washed with TFA (10 ml), combined with the cleavage mixture, and concentrated in vacuo. The crude peptide was precipitated with a 10-fold excess of cooled (Ϫ20°C) diethyl ether, leaving a white precipitate. Purification, HPLC, and MALDI-TOF analysis were performed as above.
Monitoring the RCM reaction
An analytical test for monitoring the progress of the RCM reaction was performed in a similar manner as described by Young Woo et al. (24) . A 50-l aliquot of resin suspension was taken out of the reaction and washed with 200 l of anhydrous DCE under nitrogen bubbling. After that initial wash, the reaction solution was washed with DCM and DCM/MeOH (1:1), cleaved with 60 l of cleavage mixture (TFA/H20/TIS (95:2.5: 2.5)) for 40 min, resin was removed, TFA was evaporated, and the peptide was precipitated with cold diethyl ether. The pellet was left to air-dry before dissolving it in 25 l of 95:5 water/ MeOH with 0.05% TFA and analyzed using analytical RP-HPLC.
CD helicity measurements
CD spectra were recorded on a Jasco J-810 with a total of three scans from 195 to 260 nm in 0.5-nm increments. The averaged scans were collected at a scanning speed of 200 nm/min using a 1-mm path length cell. Peptides were prepared as described in Greenfield's protocol (41) and dissolved in Mil-liQ deionized water with the target concentration between 30 and 50 M with the exact concentration then confirmed using a BCA protein assay kit according to the manufacturer's protocol. The CD spectrum of the MilliQ Water was subtracted from the spectrum of the sample.
The Jasco J-810 generates the raw output in ellipticity and is measured in millidegrees. This was first converted to molar ellipticity ([]) with units of (d ϫ c 2 )/d. Once the precise con-Stapled TM peptides modulate GPCR oligomers centration was confirmed, the molar ellipticity [] was calculated as follows. Where c is the sample concentration (M), l is the path length (mm), n is the number of peptide bonds (calculated as amino acid residues Ϫ 1), and obs is the observed ellipticity (millidegrees). To calculate the percentage of helicity, the mean residue ellipticity and MAX were calculated according to Forood et al. (42) and others (43) (44) (45) , where 222 is molar ellipticity at 222 nm, c is molar concentration of the peptide, and n is the number of amino acid residues,
where T is the temperature (273 K) and k is the number of nonhydrogen-bonded peptide carbonyls. 
Proteolytic stability studies
Stability against trypsin-To 100 l of peptide solution (100 M, dissolved in ammonium bicarbonate buffer, pH 7.5), 60 l of ammonium bicarbonate buffer (pH 7.5) was added, together with 20 l of temperature-equilibrated (37 Ϯ 1°C) trypsin (5 g/ml) from porcine pancreas (Sigma, 13,000 -20,000 BAEE units/mg of protein). Peptides were incubated for 15, 30, 60, 120, 240, and 480 min, and then MeOH (HPLC Grade) ϩ 0.05% TFA was added. The samples were then centrifuged (15,000 rpm), and the supernatant was analyzed, using Fmoc-Gly (10 l, 0.2 mM) as an internal standard. The digestion at each time point was repeated three times to give the average values along with S.D. The amount of intact peptide that remained in the mixture was quantified by RP-HPLC. The experiment was repeated twice on different days.
Stability against chymotrypsin-To 100 l of peptide solution (100 M, dissolved in ammonium bicarbonate buffer, pH 7.5), 60 l of ammonium bicarbonate buffer (pH 7.5) was added, together with 20 l of temperature-equilibrated (37 Ϯ 1°C) ␣-chymotrypsin (5 g/ml) from bovine pancreas (Sigma, Type II, activity Ͼ 40 units/mg protein). Peptides were incubated for 15, 30, 60, 120, 240, and 480 min, and then MeOH (HPLC grade) ϩ 0.05% TFA was added. The samples were then centrifuged (15,000 rpm), and supernatant was analyzed in a similar manner as described above. The experiment was repeated twice on different days.
Stability in the mouse serum-To 200 l of fresh nonsterile mouse serum was added 25 l of peptide solution (100 M, dissolved in ammonium bicarbonate buffer, pH 7.5, containing 10% DMSO), and the mixture was incubated at 37°C. At the specified time, an aliquot of incubation mixture was withdrawn and quenched by the addition of an equal volume of 15% TCA in acetonitrile to precipitate out serum proteins over ice for 30 min. The mixture was then centrifuged at 13,500 rpm for 10 min, and the supernatant was collected and analyzed by HPLC in a similar manner as described previously. The experiment was repeated twice on different days.
